Abstract
Hepatitis C virus (HCV) infection is a major global health issue. Although the search for HCV treatments has resulted in great achievements, the current treatment methods have limitations, and new methods and drugs for hepatitis C treatment are still required. The aim of the present study was to investigate the effects of artesunate (ART) on HCV replication and compared these effects with those of ribavirin (RBV) and interferon-2b (IFN). The study was performed in HCV-infection cell models (JFH1-infected Huh7.5.1 and OR6 cell lines). Our results showed that the antimalarial drug ART inhibited HCV replicon replication in a dose- and time-dependent manner at a concentration that had no effect on the proliferation of exponentially growing host cells, and the inhibitory effect on HCV replication was stronger than RBV but weaker than IFN, as determined by qPCR, luciferase assays, and Western blot analysis. Furthermore, the combination of ART and IFN resulted in a greater inhibition of HCV replication. These findings demonstrated that ART had an inhibitive effect on HCV replication and may be a novel supplemental co-therapy with IFN and RBV for HCV and as an alternative strategy to combat resistance mechanisms that have emerged in the presence of DAA agents.
Similar content being viewed by others
References
D.L. Thomas, Nat. Med. 19, 850–858 (2013)
A. Craxi, A. Licata, Semin. Liver Dis. 23(Suppl 1), 35–46 (2003)
M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, L.B. Seeff, Hepatology 54, 1433–1444 (2011)
H.W. Reesink, S. Zeuzem, C.J. Weegink, N. Forestier, A. van Vliet, D.R.J. van de Wetering, L. McNair, S. Purdy, R. Kauffman, J. Alam, P.L. Jansen, Gastroenterology 131, 997–1002 (2006)
J.M. Pawlotsky, Hepatology 53, 1742–1751 (2011)
N.J. White, Science 320, 330–334 (2008)
M. Adjuik, A. Babiker, P. Garner, P. Olliaro, W. Taylor, N. White, Lancet 363, 9–17 (2004)
X. Zhou, W.J. Sun, W.M. Wang, K. Chen, J.H. Zheng, M.D. Lu, P.H. Li, Z.Q. Zheng, Anticancer Drugs 24, 920–927 (2013)
K.T. Batty, T.M. Davis, L.T. Thu, T.Q. Binh, T.K. Anh, K.F. Ilett, J. Chromatogr. B Biomed. Appl. 677, 345–350 (1996)
W. Jiang, B. Li, X. Zheng, X. Liu, X. Pan, R. Qing, Y. Cen, J. Zheng, H. Zhou, J. Antibiot. 66, 339–345 (2013)
P.M. O’Neill, G.H. Posner, J. Med. Chem. 47, 2945–2964 (2004)
T. Efferth, M.R. Romero, D.G. Wolf, T. Stamminger, J.J. Marin, M. Marschall, Clin. Infect. Dis. 47, 804–811 (2008)
R. Arav-Boger, R. He, C.J. Chiou, J. Liu, L. Woodard, A. Rosenthal, L. Jones-Brando, M. Forman, G. Posner, PLoS One 5, e10370 (2010)
R. He, B.T. Mott, A.S. Rosenthal, D.T. Genna, G.H. Posner, R. Arav-Boger, PLoS One 6, e24334 (2011)
M.R. Romero, T. Efferth, M.A. Serrano, B. Castano, R.I. Macias, O. Briz, J.J. Marin, Antiviral Res. 68, 75–83 (2005)
K.J. Blight, J.A. McKeating, C.M. Rice, J. Virol. 76, 13001–13014 (2002)
V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann, R. Bartenschlager, Science 285, 110–113 (1999)
L.D. Presser, A. Haskett, G. Waris, Virology 412, 284–296 (2011)
M. Ikeda, K. Abe, H. Dansako, T. Nakamura, K. Naka, N. Kato, Biochem. Biophys. Res. Commun. 329, 1350–1359 (2005)
J. Paeshuyse, L. Coelmont, I. Vliegen, J. Van Hemel, J. Vandenkerckhove, E. Peys, B. Sas, E. De Clercq, J. Neyts, Biochem. Biophys. Res. Commun. 348, 139–144 (2006)
R.S. Miller, Q. Li, L.R. Cantilena, K.J. Leary, G.A. Saviolakis, V. Melendez, B. Smith, P.J. Weina, Malar J. 11, 255 (2012)
R. Price, M. van Vugt, L. Phaipun, C. Luxemburger, J. Simpson, R. McGready, F. ter Kuile, A. Kham, T. Chongsuphajaisiddhi, N.J. White, F. Nosten, Am. J. Trop. Med. Hyg. 60, 547–555 (1999)
T. Efferth, M. Marschall, X. Wang, S.M. Huong, I. Hauber, A. Olbrich, M. Kronschnabl, T. Stamminger, E.S. Huang, J. Mol. Med. 80, 233–242 (2002)
S.R. Meshnick, Y.Z. Yang, V. Lima, F. Kuypers, S. Kamchonwongpaisan, Y. Yuthavong, Antimicrob. Agents Chemother. 37, 1108–1114 (1993)
G.H. Posner, C.H. Oh, D. Wang, L. Gerena, W.K. Milhous, S.R. Meshnick, W. Asawamahasadka, J. Med. Chem. 37, 1256–1258 (1994)
J. Choi, K.J. Lee, Y. Zheng, A.K. Yamaga, M.M. Lai, J.H. Ou, Hepatology 39, 81–89 (2004)
T. Zima, M. Kalousova, Alcohol. Clin. Exp. Res. 29, 110S–115S (2005)
D. Burdette, M. Olivarez, G. Waris, J. Gen. Virol. 91, 681–690 (2010)
G. Waris, A. Livolsi, V. Imbert, J.F. Peyron, A. Siddiqui, J. Biol. Chem. 278, 40778–40787 (2003)
Acknowledgments
We thank Dr. Chung (Harvard University) for providing Huh7.5.1 cells and JFH1 and Dr. Zhao (Chinese Academy of Sciences) for providing OR6 cells. This work was supported by Grants from the National Natural Science Fund of China (81370542), Chinese National Key Clinical Specialty Project (No. 2013), and Chinese National Science and Technology Major Project (No. 2008ZX10202, http://www.nmp.gov.cn/) to GZ Gong.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by Paul Schnitzler.
Rights and permissions
About this article
Cite this article
Dai, R., Xiao, X., Peng, F. et al. Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication. Virus Genes 52, 22–28 (2016). https://doi.org/10.1007/s11262-015-1285-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11262-015-1285-7